natgillin/translations-raw huggingface dataset:
Entacapone showed little or no inhibition of other types of P450 isoenzymes (CYP1A2, CYP2A6, CYP2D6, CYP2E1, CYP3A and CYP2C19) (see section 4.5).
Entakapon je pokazao malo ili nikakvo inhibiranje drugih tipova P450 izoenzima (CYP1A2, CYP2A6, CYP2D6, CYP2E1, CYP3A i CYP2C19) (vidjeti dio 4.5).
Entacapone Teva entacapone
Entacapone Teva entakapon
Entacapone Teva in association with levodopa may have major influence on the ability to drive and use machines.
Entakapon Teva udružen s levodopom može imati velik utjecaj na sposobnost upravljanja vozilima i strojevima.
Entacapone Teva is a medicine that contains the active substance entacapone.
Entacapone Teva lijek je koji sadrži djelatnu tvar entakapon.
Entacapone Teva is a ‘generic medicine’.
Entacapone Teva> je „generički lijek”.
Entacapone Teva is available in HDPE tablet containers with polypropylene screw caps with desiccant insert containing 30, 60, 100 or 175 film-coated tablets.
Entakapon Teva je dostupan u HDPE spremnicima za tablete s polipropilenskim zatvaračem s navojem te umetnutim sredstvom za sušenje koje sadrže 30, 60 100 ili 175 filmom obloženih tableta.
Entacapone Teva is taken together with medicines containing levodopa (either levodopa/carbidopa preparations or levodopa/benserazide preparations).
Entakapon Teva se uzima zajedno s lijekovima koji sadrže levodopu (lijekovi koji sadrže ili kombinaciju levodope/karbidope ili kombinaciju levodope/benzerazida).
Entacapone Teva is used to treat patients with Parkinson’s disease.
Entacapone Teva se koristi za liječenje bolesnika s Parkinsonovom bolesti.
Entacapone Teva is used together with levodopa (either a combination of levodopa and benserazide or a combination of levodopa and carbidopa) when the patient is having ‘fluctuations’ towards the end of the period between two doses of their medication.
Entacapone Teva koristi se zajedno s lijekom levodopa (kombinacija levodope i benserazida ili kombinacija levodope i karbidope) u bolesnika koji imaju „fluktuacije” prema kraju razdoblja između dviju doza lijeka.
Entacapone Teva tablets contain entacapone and are used together with levodopa to treat Parkinson’s disease.
Entakapon Teva tablete sadrže entakapon i primjenjuju se zajedno s levodopom za liječenje Parkinsonove bolesti.
Entacapone Teva taken together with levodopa may lower your blood pressure, which may make you feel light-headed or dizzy.
Entakapon Teva uzet zajedno s levodopom može sniziti Vaš krvni tlak zbog čega možete osjetiti laganu ošamućenost ili omaglicu.
Entacapone Teva taken with levodopa may cause drowsiness and may cause you to sometimes suddenly fall asleep.
Entakapon Teva uzet s levodopom može izazvati pospanost i može dovesti do toga da ponekad iznenada utonete u san.
Entacapone Teva taken with levodopa may rarely make you feel very drowsy during the day, and cause you to suddenly fall asleep;
U rijetkim slučajevima, nakon istodobnog uzimanja Entakapona Teva i levodope, može se dogoditi da tijekom dana osjetite prekomjernu pospanost ili da naglo utonete u san;
Entecavir
C24 1,82 (1,39; 2,39)
Entecavir
Entekavir
Entecavir-TP is a weak inhibitor of cellular DNA polymerases α, β, and δ with Ki values of 18 to 40 µM. In addition, high exposures of entecavir had no relevant adverse effects on γ polymerase or mitochondrial DNA synthesis in HepG2 cells (Ki > 160 µM).
Entekavir-TP slabi je inhibitor staničnih DNK polimeraza α, β i δ s vrijednostima Ki od 18 do 40 µM. Uz to, visoke izloženosti entekaviru nisu imale štetne učinke na γ polimerazu ili sintezu mitohondrijske DNK u HepG2 stanicama (Ki > 160 µM).
enteric-coated didanosine, but
kapsulama didanozina, ali je
Enteric-coated microtablets
Acidorezistentne mikrotablete
Enteritis Intestinal obstruction
Enteritis Crijevna opstrukcija
Enterobacteriaceae: S ≤ 0.5 mg/L and R > 1 mg/L
Enterobacteriaceae: S ≤0,5 mg/l i R >1 mg/l
Enterococci including Enterococcus faecalis and Enterococcus faecium
Enterokoki uključujući Enterococcus faecalis i Enterococcus faecium
Enterocolitis haemorrhagic Gastrointestinal haemorrhage Pancreatitis acute
Enterokolitis, hemoragijski Gastrointestinalno krvarenje Pankreatitis, akutni
enterocolitis, including neutropaenic colitis, caecitis*
enterokolitis, uključujući neutropenijski kolitis, upala slijepog crijeva
Enterocutaneous fistula
enterokutana fistula
Enterocutaneous fistula
enterokutane fistule
Enthesitis Resolution n (%) ‡
Povlačenje entezitisa n (%)
Enthesitis-related arthritis
artritisa povezanog s entezitisom
Entire male pigs from 8 weeks of age onwards should be vaccinated with 2 doses of 2 ml at least 4 weeks apart, with the second dose normally given 4 to 6 weeks prior to slaughter.
Nerasti od 8 tjedana starosti nadalje trebaju se cijepiti dvjema dozama od 2 ml u razmaku od najmanje 4 tjedna, a druga se doza obično primjenjuje 4 do 6 tjedana prije klanja.
Entire patient population
Cijela populacija bolesnika
Entire study periodd
Cijelo razdoblje ispitivanjad
Entresto (N=4
Enalapril Entresto (
Entresto (N=4
Entresto 4187
Entresto 24 mg/26 mg film-coated tablets are violet-white oval tablets with “NVR” on one side and “LZ” on the other side.
Entresto 24 mg/26 mg filmom obložene tablete su ljubičasto bijele ovalne tablete s oznakom „NVR“ s jedne strane i „LZ“ s druge strane.
Entresto 24 mg/26 mg film-coated tablets EU/1/15/1058/001
Entresto 24 mg/26 mg filmom obložene tablete EU/1/15/1058/001
Entresto 24 mg/26 mg film-coated tablets Hypromellose, substitution type 2910 (3 mPa·s) Titanium dioxide (E171)
Entresto 24 mg/26 mg filmom obložene tablete Hipromeloza, supstitucijski tip 2910 (3 mPa s) Titanijev dioksid (E171)
Entresto 49 mg/51 mg film-coated tablets Hypromellose, substitution type 2910 (3 mPa·s) Titanium dioxide (E171)
Entresto 49 mg/51 mg filmom obložene tablete Hipromeloza, supstitucijski tip 2910 (3 mPa s) Titanijev dioksid (E171)
Entresto 49 mg/51 mgfilm-coated tablets sacubitril/valsartan
Entresto 49 mg/51 mg filmom obložene tablete sakubitril/valsartan
Entresto 97 mg/103 mg film-coated tablets are light pink oval tablets with “NVR” on one side and “L11” on the other side.
Entresto 97 mg/103 mg filmom obložene tablete su svijetlo ružičaste ovalne tablete s oznakom „NVR“ s jedne strane i „L11“ s druge strane.
Entresto 97 mg/103 mg film-coated tablets EU/1/15/1058/005-007
Entresto 97 mg/103 mg filmom obložene tablete EU/1/15/1058/005-007
Entresto 97 mg/103 mg film-coated tablets Hypromellose, substitution type 2910 (3 mPa·s) Titanium dioxide (E171)
Entresto 97 mg/103 mg filmom obložene tablete Hipromeloza, supstitucijski tip 2910 (3 mPa s) Titanijev dioksid (E171)
Entresto contains valsartan, and therefore should not be co-administered with another ARB containing product (see section 4.4).
Entresto sadrži valsartan pa se stoga ne smije primjenjivati zajedno s drugim lijekom koji sadrži ARB (vidjeti dio 4.4).
Entresto contains valsartan, and therefore should not be co-administered with another ARB containing product (see sections 4.2 and 4.5).
Entresto sadrži valsartan i stoga se ne smije primjenjivati zajedno s drugim lijekom koji sadrži ARB (vidjeti dijelove 4.2 i 4.5).
Entresto must not be initiated until 36 hours after taking the last dose of ACE inhibitor therapy.
Entresto se ne smije započinjati do 36 sati nakon uzimanja zadnje doze terapije ACE inhibitorom.
Entresto must not be started until 36 hours after taking the last dose of ACE inhibitor therapy.
Primjena Entresta ne smije se započinjati do 36 sati nakon uzimanja zadnje doze terapije ACE inhibitorom.
Entresto should not be co-administered with an ACE inhibitor or an ARB.
Entresto se ne smije primjenjivati istodobno s ACE inhibitorom ili ARB-om.
Entresto’s serious side effects in the main study were similar to those of enalapril, which is already authorised for use in heart failure.
Ozbiljne nuspojave lijeka Entresto otkrivene u glavnom ispitivanju slične su onima enalaprila, koji je već odobren za primjenu pri zatajenju srca.
Entyvio 300 mg powder for concentrate for solution for infusion
Entyvio 300 mg prašak za koncentrat za otopinu za infuziju
Entyvio 300 mg powder for concentrate for solution for infusion in Type 1 glass vial (20 ml) fitted with rubber stopper and aluminium crimp protected by a plastic cap.
Entyvio 300 mg prašak za koncentrat za otopinu za infuziju u staklenoj bočici tipa 1 (20 ml) opremljen gumenim čepom i aluminijskim prstenom zaštićenim plastičnim zatvaračem.
Entyvio 300 mg powder for concentrate for solution for infusion Vedolizumab
Entyvio 300 mg prašak za koncentrat za otopinu za infuziju vedolizumab
Entyvio 300 mg powder for concentrate for solution for infusion Vedolizumab For intravenous use after reconstitution and dilution.
Entyvio 300 mg prašak za koncentrat za otopinu za infuziju vedolizumab Za primjenu u venu nakon rekonstitucije i razrjeđivanja.
Entyvio does not contain preservatives.
Entyvio ne sadrži konzervanse.
Entyvio is a white to off-white powder for concentrate for solution for infusion provided in a glass vial with a rubber stopper and a plastic cap.
Entyvio je bijeli do gotovo bijeli prašak za koncentrat za otopinu za infuziju koji se isporučuje u staklenoj bočici s gumenim čepom i plastičnim zatvaračem.
Entyvio is for intravenous use only.
Entyvio je namijenjen isključivo za intravensku primjenu.
Entyvio is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα) antagonist.
Entyvio je indiciran za liječenje odraslih bolesnika s umjereno do izrazito aktivnom Crohnovom bolesti koji nisu postigli odgovarajući odgovor ili su izgubili odgovor ili na standardnu terapiju ili na antagoniste faktora nekroze tumora alfa (TNFα), te onih koji takvu terapiju nisu podnosili.
Entyvio is produced by a method known as ‘recombinant DNA technology’; it is made by cells into which a gene (DNA) has been introduced that makes them able to produce vedolizumab.
Entyvio se proizvodi metodom poznatom pod nazivom „tehnologija rekombinantne DNK”; nastaje u stanicama u koje se uvodi gen (DNK), što ih čini sposobnim za proizvodnju vedolizumaba.
Entyvio is to be used during pregnancy only if the benefits clearly outweigh any potential risk to both the mother and foetus.
Entyvio se smije koristiti tijekom trudnoće samo ako prednosti jasno nadilaze bilo koji potencijalni rizik i za majku i za plod.
Entyvio may have a minor influence on the ability to drive or operate machines, as dizziness has been reported in a small number of patients.
Entyvio može imati mali utjecaj na sposobnost upravljanja vozilima ili rada sa strojevima jer je omaglica zapažena u malom broju bolesnika.
Entyvio should be at room temperature (20°C-25°C) when reconstituted.
Entyvio prije rekonstitucije treba doseći sobnu temperaturu (20°C-25°C).
Entyvio should be at room temperature (20°C-25°C) when reconstituted.
Entyvio treba prije rekonstitucije doseći sobnu temperaturu (20°C -25°C).
Entyvio treatment should be initiated and supervised by specialist healthcare professionals experienced in the diagnosis and treatment of ulcerative colitis or Crohn’s disease (see section 4.4).
Liječenje lijekom Entyvio treba započeti i nadzirati liječnik specijalist s iskustvom u dijagnosticiranju i liječenju ulceroznog kolitisa ili Crohnove bolesti (vidjeti dio 4.4).
Entyvio was also shown to be more effective than placebo at improving symptoms of Crohn’s disease.
Entyvio se također pokazao djelotvornijim od placeba u poboljšavanju simptoma Crohnove bolesti.
Enuresis
enureza
Enuresis, renal cyst, pollakiuria, urine colour abnormal
enureza, renalna cista, polakizurija, abnormalna boja mokraće
Enurev Breezhaler 44 micrograms inhalation powder, hard capsules glycopyrronium (glycopyrronium bromide)
Enurev Breezhaler 44 mikrograma prašak inhalata, tvrde kapsule glikopironij (glikopironijev bromid)
Enurev Breezhaler is a once-daily, long-term maintenance treatment and is not indicated for the initial treatment of acute episodes of bronchospasm, i.e. as a rescue therapy.
Enurev Breezhaler je dugoročna terapija održavanja koja se primjenjuje jedanput na dan i nije indiciran za inicijalno liječenje akutnih epizoda bronhospazama, tj. kao terapija u hitnim slučajevima.
Enurev Breezhaler is an inhaled long-acting muscarinic receptor antagonist (anticholinergic) for once-daily maintenance bronchodilator treatment of COPD.
Enurev Breezhaler je inhalacijski dugodjelujući antagonist muskarinskih receptora (antikolinergik) za održavanje bronhodilatacijskog liječenja KOPB-a jedanput na dan.
Enurev Breezhaler once daily statistically significantly reduced the use of rescue medication (salbutamol) by 0.46 puffs per day (p=0.005) over 26 weeks and by 0.37 puffs per day (p=0.039) over 52 weeks, compared to placebo for the 6- and 12-month studies, respectively.
Enurev Breezhaler jedanput na dan statistički značajno je smanjio korištenje lijeka za hitne slučajeve (salbutamola) za 0,46 udisaja dnevno (p=0,005) tijekom 26 tjedana, odnosno za 0,37 udisaja dnevno (p=0,039) tijekom 52 tjedna, u usporedbi s placeboom za 6-mjesečno odnosno 12-mjesečno ispitivanje.
Enurev Breezhaler with food and drink
Enurev Breezhaler s hranom i pićem
Envarsus 0.75 mg prolonged-release tablets are oval, white to off-white uncoated tablet, debossed with “0.75” on one side and “TCS” on the other side.
Envarsus 0,75 mg tablete s produljenim oslobađanjem su ovalne, bijele do bjelkaste neobložene tablete, s utisnutom oznakom „0,75“ na jednoj strani i „TCS“ na drugoj strani.
Envarsus 0.75 mg prolonged-release tablets Tacrolimus
Envarsus 0,75 mg tablete s produljenim oslobađanjem Tacrolimus
Envarsus 0.75 mg prolonged-release tablets Tacrolimus
Envarsus 0,75 mg tablete s produljenim oslobađanjem takrolimus
Envarsus 1 mg prolonged-release tablets Tacrolimus
Envarsus 1 mg tablete s produljenim oslobađanjem Tacrolimus
Envarsus 1 mg prolonged-release tablets Tacrolimus
Envarsus 1 mg tablete s produljenim oslobađanjem takrolimus
Envarsus 4 mg prolonged-release tablets Tacrolimus
Envarsus 4 mg tablete s produljenim oslobađanjem Tacrolimus
Envarsus 4 mg prolonged-release tablets Tacrolimus
Envarsus 4 mg tablete s produljenim oslobađanjem takrolimus
Envarsus contains lactose.
Envarsus sadrži laktozu.
Envarsus is a prolonged-release formulation of tacrolimus resulting in an extended oral absorption profile with an average time to maximum blood concentration (Cmax) of approximately 6 hours (tmax) at steady state.
Envarsus je farmaceutski oblik takrolimusa s produljenim oslobađanjem što rezultira produljenim apsorpcijskim profilom nakon peroralne primjene uz prosječno vrijeme do postizanja maksimalne koncentracije u krvi (Cmax) od otprilike 6 sati (tmax) u stanju dinamičke ravnoteže.
Envarsus is a ‘hybrid medicine’.
Envarsus je „hibridni lijek”.
Envarsus is not interchangeable with other existing tacrolimus containing medicines (immediate release or prolonged release) on an equal dose by dose basis.
Envarsus nije zamjenjiv s drugim postojećim lijekovima koji sadrže takrolimus (s trenutnim ili produljenim oslobađanjem) na osnovi jednakih doza.
Envarsus is not recommended for use in children below 18 years of age due to the limited data on safety and/or efficacy
Ne preporučuje se primjena Envarsusa u djece mlađe od 18 godina, zbog ograničenih podataka o sigurnosti i/ili djelotvornosti.
Envarsus is routinely administered in conjunction with other immunosuppressive agents in the initial post- operative period.
Envarsus se rutinski primjenjuje zajedno s drugim imunosupresivnim lijekovima u ranom postoperativnom razdoblju.
Envarsus is taken orally once daily, generally on an empty stomach.
Envarsus se uzima kroz usta jedanput na dan, obično na prazan želudac.
Envarsus is used to control your body’s immune response, enabling your body to accept the transplanted organ.
Envarsus se primjenjuje za kontrolu imunološkog odgovora Vašeg tijela, čime se Vašem tijelu omogućuje da prihvati presađeni organ.
Envarsus should be administered in the morning.
Envarsus se mora uzimati ujutro.
Envarsus therapy requires careful monitoring by adequately qualified and equipped personnel.
Liječenje Envarsusom mora biti pod pažljivim nadzorom odgovarajuće obučenih i opremljenih zdravstvenih djelatnika.
Envarsus therapy should be initiated after considering ciclosporin blood concentrations and the clinical condition of the patient.
Liječenje Envarsusom treba započeti nakon što se provjere koncentracija ciklosporina u krvi i kliničko stanje bolesnika.
Envarsus therapy should commence at a dose of 0.11 – 0.13 mg/kg/day administered once daily in the morning.
Liječenje Envarsusom treba započeti dozom od 0,11 - 0,13 mg/kg/dan koja se primjenjuje jedanput na dan, ujutro.
Environmental properties
Svojstva koja se tiču zaštite okoliša
Environmental Risk Assessment
Procjena rizika za okoliš
Environmental Risk Assessment (ERA)
Procjena rizika za okoliš
Environmental Risk Assessment (ERA):
Procjena rizika za okoliš:
Environmental Risk Assessment (ERA): no environmental impact is anticipated from the clinical use of pioglitazone.
Procjena rizika za okoliš (ERA): ne očekuje se utjecaj na okoliš tijekom kliničke primjene pioglitazona.
Environmental risk assessment studies have shown that bedaquiline has the potential to be persistent, bioaccumulative and toxic to the environment (see section 6.6).
Ispitivanja procjene rizika za okoliš pokazale su da je bedakilin potencijalno postojan, bioakumulativan i toksičan za okoliš (vidjeti dio 6.6).
Enyglid 0.5 mg tablets Repaglinide
Enyglid 0,5 mg tablete repaglinid
Enyglid 1 mg tablets Repaglinide
Enyglid 1 mg tablete repaglinid
Enyglid 2 mg tablets Repaglinide
Enyglid 2 mg tablete repaglinid
Enyglid is a ‘generic medicine’.
Enyglid je generički lijek.
enzalutamide
enzalutamid
Enzalutamide (N = 800)
Enzalutamid (N = 800)
Enzalutamide (N = 872)
Enzalutamid (N = 872)
Enzalutamide competitively inhibits binding of androgens to androgen receptors, inhibits nuclear translocation of activated receptors and inhibits the association of the activated androgen receptor with DNA even in the setting of androgen receptor overexpression and in prostate cancer cells resistant to anti-androgens.
Enzalutamid kompetitivno inhibira vezanje androgena na androgene receptore, inhibira translokaciju aktiviranih receptora u jezgru i inhibira povezivanje aktiviranog androgenog receptora s DNK čak i kod pretjerane izraženosti androgenih receptora i u stanicama karcinoma prostate rezistentnima na antiandrogene.
Enzalutamide did not induce mutations in the microbial mutagenesis (Ames) assay and was not clastogenic in either the in vitro cytogenetic assay with mouse lymphoma cells or the in vivo mouse micronucleus assay.
Enzalutamid nije izazvao mutacije na testu mikrobiološke mutageneze (Amesov test) i nije bio klastogen ni u in vitro citogenetskom testu na stanicama mišjeg limfoma niti u in vivo mišjem mikronukleusnom testu.
Enzalutamide does this by blocking the receptors to which these hormones attach and preventing them from responding.
Enzalutamid to čini blokirajući receptore na koje se ovi hormoni vežu te sprječava njihovu reakciju.
Enzalutamide is contraindicated in women who are or may become pregnant (see sections 4.3 and 5.3).
Enzalutamid je kontraindiciran u trudnica ili žena koje mogu zatrudnjeti (vidjeti dijelove 4.3 i 5.3).
Enzalutamide is extensively metabolized.
Enzalutamid se opsežno metabolizira.
Enzalutamide is metabolized by CYP2C8 and to a lesser extent by CYP3A4/5 (see section 4.5), both of which play a role in the formation of the active metabolite.
Enzalutamid metabolizira CYP2C8 i u manjoj mjeri CYP3A4/5 (vidjeti dio 4.5), od kojih oba igraju ulogu u stvaranju djelatnog metabolita.
Enzalutamide may have a moderate influence on the ability to drive and use machines as psychiatric and neurologic events including seizure have been reported (see section 4.8).
Enzalutamid može umjereno utjecati na sposobnost upravljanja vozilima i rada na strojevima, jer su zabilježeni psihijatrijski i neurološki učinci, uključujući napadaje (vidjeti dio 4.8).
Enzalutamide significantly decreased the risk of the first skeletal-related event by 28% [HR = 0.718 (95% CI: 0.610, 0.844) p-value < 0.0001].
Enzalutamid je značajno smanjio rizik za pojavu prvog koštanog događaja za 28% [HR = 0,718 (95% CI: 0,610; 0,844) p-vrijednost < 0,0001].
Enzalutamide treatment decreases the growth of prostate cancer cells and can induce cancer cell death and tumour regression.
Liječenje enzalutamidom smanjuje rast stanica karcinoma prostate i može inducirati smrt stanica karcinoma te povlačenje tumora.
Enzepi (N=83)
Enzepi
Enzepi 10,000 units gastro-resistant hard capsules Pancreas powder
Enzepi 10 000 jedinica želučanootporne tvrde kapsule gušterača, prašak
Enzepi 25,000 units gastro-resistant hard capsules Pancreas powder
Enzepi 25 000 jedinica želučanootporne tvrde kapsule gušterača, prašak
Enzepi 40,000 units gastro-resistant hard capsules Pancreas powder
Enzepi 40 000 jedinica želučanootporne tvrde kapsule gušterača, prašak
Enzepi 40,000 units gastro-resitant hard capsules
Enzepi 40 000 jedinica želučanootporne tvrde kapsule
Enzepi 5,000 units gastro-resistant hard capsules Pancreas powder
Enzepi 5000 jedinica želučanootporne tvrde kapsule gušterača, prašak
Enzepi capsules or the granules inside them should not be crushed or chewed and the capsules or the granules inside them should not be held in your or your child’s mouth.
Kapsule Enzepi ili granule u njima ne smiju se drobiti niti žvakati; kapsule ili granule u njima ne smijete držati u ustima, niti ih Vaše dijete smije držati u ustima.
Enzepi does not affect your ability to drive or use tools or machines.
Enzepi ne utječe na Vašu sposobnost upravljanja vozilima ili rada na strojevima.
Enzepi is for use by adults, adolescents, children and infants with ‘exocrine pancreatic insufficiency’, a condition that makes the body less able to break down and digest food.
Enzepi je namijenjen odraslima, adolescentima, djeci i dojenčadi s "egzokrinom insuficijencijom gušterače", stanjem koje otežava tijelu razgradnju i probavu hrane.
Enzepi should not be crushed or chewed or mixed in foods having a pH greater than 5.
Enzepi se ne smije drobiti, žvakati niti miješati s hranom čiji je pH veći od 5.
enzyme increased
povišena kreatin
Enzyme inducers (such as St. John’s wort [Hypericum perforatum], rifampicin, barbiturates, phenytoin, carbamazepine, ritonavir, efavirenz) may give rise to decreased exposure of canagliflozin.
Induktori enzima (poput gospine trave [Hypericum perforatum], rifampicin, barbiturati, fenitoin, karbamazepin, ritonavir, efavirenz) mogu dovesti do smanjene izloženosti kanagliflozinu.
Enzyme inducing medicinal products such as rifampicin, carbamazepine, phenytoin, phenobarbital, St. John’s wort (Hypericum perforatum) are likely to lead to reduced piperaquine plasma concentrations.
Lijekovi koji induciraju enzime, kao što su rifampicin, karbamazepin, fenitoin, fenobarbital, gospina trava (Hypericum perforatum), vjerojatno će dovesti do sniženja koncentracije piperakina u plazmi.
Enzyme induction wears off slowly and effects on the plasma concentrations of ulipristal acetate may occur even if a woman has stopped taking an enzyme inducer within the last 2-3 weeks.
Kako indukcija enzima postepeno slabi, učinci na koncentraciju ulipristalacetata u plazmi mogu se pojaviti čak i nakon što žena prekine uzimati lijek induktor enzima unutar prethodna 2 – 3 tjedna.
Enzyme induction: Exposure to zonisamide is lower in epileptic patients receiving CYP3A4-inducing agents such as phenytoin, carbamazepine, and phenobarbitone.
Indukcija enzima: izloženost zonisamidu manja je u bolesnika s epilepsijom koji primaju lijekove koji induciraju CYP3A4, kao što su fenitoin, karbamazepin i fenobarbiton.
Enzyme-inducing drugs such as rifampicin, rifabutin, carbamazepine, isoniazid, nevirapine, mitotane and phenytoin may significantly reduce the bioavailability of Ketoconazole HRA.
Lijekovi koji induciraju enzime poput rifampicina, rifabutina, karbamazepina, izoniazida, nevirapina, mitotana i fenitoina mogu značajno smanjiti bioraspoloživost Ketoconazolea HRA.
enzymes*, abnormal liver function test
hepatocelularna*, hepatitis, povišenje jetrenih enzima*, poremećene vrijednosti testova jetrene funkcije
enzymes, a similar
očekuje se slično